Month: June 2022

Also Announces Change of Auditors in Connection with Qualifying Transaction CALGARY, Alberta, June 10, 2022 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP Realty”) (TSXV: AIP.U) announces that the Trust has filed, and obtained a receipt for, a preliminary prospectus in connection with a marketed offering of trust units (the “Units”) at a price of US$2.00 per Unit (the “Offering Price”) for aggregate gross proceeds of up to US$25 million (not including the exercise of the Over-Allotment Option (as defined herein)) (the “Offering”). The Units will be offered for sale on a “best efforts” agency basis pursuant to an agency agreement (the “Agency Agreement”) to be entered into between the Trust and Laurentian Bank Securities Inc. and Raymond James Ltd. (the “Co-Lead Agents”) and iA Private Wealth Inc. and Canaccord Genuity...

Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Credit Suisse Group AG has notified Zealand about a change of its total holding of shares and voting rights, in accordance with section 38 of the Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Capital Markets Act and financial instruments with similar economic effect according to section 39(2)(2) of the Capital Markets...

Villers-lès-Nancy, 10 June 2022 – 6:30 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY GENERAL MEETING MEETING NOTICE ON-LINE AVAILABILITY OF MEETING MATERIALS EQUASENS (formally PHARMAGEST INTERACTIVE) hereby provides notice to shareholders of the Annual Ordinary General Meeting to be held on Thursday, June 28, 2022 at 5.00 pm at the Company’s registered office located in Villers-lès-Nancy (Technopôle de Nancy-Brabois – 5 Allée de Saint Cloud). The original French language version of the agenda and the resolutions submitted by the Board of Directors to the Ordinary Annual General Meeting were published in the French publication for legal announcements (Bulletin des Annonces Légales Obligatoires) on 20 May, 2022 (https://www.journal-officiel.gouv.fr/pages/balo-annonce-unitaire/?q.id=id_annonce:20220520220195760). The Meeting Notice...

Selskabsmeddelelse Nr. 11/2022 10. juni 2022 Indeholder intern videnDanske Erria har vundet selskabets største kontrakt nogensinde med Ørsted og opjusterer i denne forbindelse guidance med 2 mio. kr. Kontrakten er femårig med mulighed for forlængelse i yderligere to år. Ørsted Bioenergy & Thermal Power A/S (Ørsted) estimerer kontraktsummen til maksimalt 450.000.000 DKK.Med den historisk store Ørsted-kontrakt åbner offshore-konglomeratet med base på det historiske handelstorv i Køge et nyt kapitel i selskabets 30-årige historie. Erria A/S (“Erria” eller “selskabet”) har tidligere gennem 15 år indtil 2017 leveret drift, service, risikostyring og sikkerhedsudstyr til Ørsted, og nu er Danmarks største energivirksomhed igen at finde på kundelisten.CEO Henrik N. Andersen ser frem til igen at servicere en af Danmarks største virksomheder...

Drawing of a tranche of ORNAN of €1 million in nominal value Dardilly, June 10, 2022 – 6.30 pm As announced on May 10, 2022, by way of a press release, the second part of the financing transaction agreed between Delta Drone and Yorkville Advisors results in the draw today of the second tranche of € 1 million, accompanied by the immediate purchase by Delta Drone of the attached BSAs for a total price of € 1. These BSAs will be cancelled. In accordance with the delegation of competence conferred on the Board of Directors by the Extraordinary General Meeting of Shareholders of Delta Drone (the “Company“) on April 24, 2020 under the terms of its 6th resolution, the Board of Directors has, on October 14, 2020:approved the principle of an issue of 2,500 warrants (the “Warrants“), which will give rise, on exercise, to...

Saint-Herblain (France), June 10, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today provides an update on its European inactivated whole-virus COVID-19 vaccine candidate VLA2001. Following receipt of the European Commission (EC)’s notice of intent to terminate the Advance Purchase Agreement (APA)1, Valneva proposed a remediation plan, which is now subject to further discussion within the EC and among the participating member states. Some member states have confirmed their interest in having an inactivated, adjuvanted whole-virus vaccine solution in their portfolio. However, the preliminary, unofficial volume indications received from the EC would not be sufficient to ensure the sustainability of Valneva’s COVID-19 vaccine program. This would also impede the future development of the program beyond...

CHARLOTTE, N.C., June 10, 2022 (GLOBE NEWSWIRE) — Glatfelter Corporation (NYSE: GLT) a leading global supplier of engineered materials, today announced that Dante C. Parrini, Chairman and Chief Executive Officer, and Ramesh Shettigar, Senior Vice President, Chief Financial Officer and Treasurer, will be presenting at the Sidoti & Company Summer Small Cap Virtual Conference on Thursday June 16, 2022. Glatfelter’s presentation will begin at 10:45 am Eastern Time. In addition, management will conduct one-on-one meetings with conference participants. A copy of the Company’s presentation, along with the webcast link, will be available on Glatfelter’s Investors page located at Webcasts and Presentations – Glatfelter Engineered Materials. About Glatfelter Glatfelter is a leading global supplier of engineered materials with...

New York, NY, and Tel Aviv, ISRAEL, June 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 45 update from an ongoing case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in February 2021 and experienced symptoms of Long COVID. ABSTRACT:The subject is a 46-year-old, 6’0”, 210 pounds, unvaccinated male who describes his premorbid condition as healthy with 5 days per week of vigorous exercise and held a physically demanding job. By report, his blood pressure was 120/75 with a resting heart rate of 60 bpm. He tested positive for COVID-19...